Current Environment: Production

Daphne Haas-Kogan | Education

Medical School

University of California, San Francisco

1991, San Francisco, CA

Residency

Radiation Oncology

University of California, San Francisco

1997, Boston, MA

Fellowship

Research

University of California, San Francisco, Diller Family Comprehensive Cancer Center

1994, San Francisco, MA

Daphne Haas-Kogan | Certifications

  • American Board of Radiology (Radiation Oncology)

Daphne Haas-Kogan | Professional History

Dr. Haas-Kogan received her medical degree from the University of California at San Francisco (UCSF) in 1991. She completed a research fellowship, followed by residency in radiation oncology at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). She spent 18 years as a radiation oncologist, researcher and academic leader in the UCSF HDFCCC system before becoming Chair of the Department of Radiation Oncology at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital in 2015.

Daphne Haas-Kogan | Publications

  1. Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Clin Cancer Res. 2024 Dec 02; 30(23):5494. View Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Abstract

  2. Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients. Clin Cancer Res. 2024 Nov 08. View Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients. Abstract

  3. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions. Neuro Oncol. 2024 Oct 23. View Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions. Abstract

  4. Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypes. Breast Cancer Res Treat. 2024 Oct 05. View Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypes. Abstract

  5. When Best Care Takes a Back Seat to the Bottom Line. JAMA Oncol. 2024 Oct 01; 10(10):1311-1312. View When Best Care Takes a Back Seat to the Bottom Line. Abstract

  6. Multimodal Deep Learning Improves Recurrence Risk Prediction in Pediatric Low-Grade Gliomas. Neuro Oncol. 2024 Aug 30. View Multimodal Deep Learning Improves Recurrence Risk Prediction in Pediatric Low-Grade Gliomas. Abstract

  7. Integrating Audiovisual Immersion Into Pediatric Radiation Therapy Across Multiple Centers: Methodology, Timeliness, and Cost of the Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy Prospective Multi-Institutional Trial. Adv Radiat Oncol. 2024 Oct; 9(10):101589. View Integrating Audiovisual Immersion Into Pediatric Radiation Therapy Across Multiple Centers: Methodology, Timeliness, and Cost of the Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy Prospective Multi-Institutional Trial. Abstract

  8. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro Oncol. 2024 Aug 05; 26(8):1367-1387. View DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Abstract

  9. NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy. Int J Radiat Oncol Biol Phys. 2024 Jul 25. View NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy. Abstract

  10. Stepwise Transfer Learning for Expert-level Pediatric Brain Tumor MRI Segmentation in a Limited Data Scenario. Radiol Artif Intell. 2024 Jul; 6(4):e230254. View Stepwise Transfer Learning for Expert-level Pediatric Brain Tumor MRI Segmentation in a Limited Data Scenario. Abstract

  11. Longitudinal risk prediction for pediatric glioma with temporal deep learning. medRxiv. 2024 Jun 28. View Longitudinal risk prediction for pediatric glioma with temporal deep learning. Abstract

  12. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiother Oncol. 2024 09; 198:110384. View Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Abstract

  13. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. EJNMMI Res. 2024 Jun 13; 14(1):54. View Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. Abstract

  14. Case Report: Low-grade glioma with NF1 loss of function mimicking diffuse intrinsic pontine glioma. Front Surg. 2024; 11:1356660. View Case Report: Low-grade glioma with NF1 loss of function mimicking diffuse intrinsic pontine glioma. Abstract

  15. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. Radiol Artif Intell. 2024 May; 6(3):e230333. View Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. Abstract

  16. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae035. View Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study. Abstract

  17. A Multi-Institutional Survey of Radiation Oncology Professionals' Knowledge, Attitudes, and Practice Behaviors Toward Sexual and Gender Minority Patients With Cancer. Adv Radiat Oncol. 2024 May; 9(5):101461. View A Multi-Institutional Survey of Radiation Oncology Professionals' Knowledge, Attitudes, and Practice Behaviors Toward Sexual and Gender Minority Patients With Cancer. Abstract

  18. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. Res Sq. 2024 Jan 18. View Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. Abstract

  19. Comparison of volumetric and 2D-based response methods in the PNOC-001 pediatric low-grade glioma clinical trial. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdad172. View Comparison of volumetric and 2D-based response methods in the PNOC-001 pediatric low-grade glioma clinical trial. Abstract

  20. Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. medRxiv. 2023 Nov 22. View Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. Abstract

  21. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024 Feb 01; 42(4):441-451. View Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. Abstract

  22. Automated temporalis muscle quantification and growth charts for children through adulthood. Nat Commun. 2023 11 09; 14(1):6863. View Automated temporalis muscle quantification and growth charts for children through adulthood. Abstract

  23. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence. Clin Transl Radiat Oncol. 2024 Jan; 44:100697. View Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence. Abstract

  24. Genetic architecture of the acute and persistent immune cell response after radiation exposure. Cell Genom. 2023 Nov 08; 3(11):100422. View Genetic architecture of the acute and persistent immune cell response after radiation exposure. Abstract

  25. A genomic score to predict local control among patients with brain metastases managed with radiation. Neuro Oncol. 2023 10 03; 25(10):1815-1827. View A genomic score to predict local control among patients with brain metastases managed with radiation. Abstract

  26. Expert-level pediatric brain tumor segmentation in a limited data scenario with stepwise transfer learning. medRxiv. 2023 Sep 18. View Expert-level pediatric brain tumor segmentation in a limited data scenario with stepwise transfer learning. Abstract

  27. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023 Dec 20; 41(36):5524-5535. View Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Abstract

  28. Radiotherapy for Primary Pediatric Central Nervous System Malignancies: Current Treatment Paradigms and Future Directions. Pediatr Neurosurg. 2023; 58(5):356-366. View Radiotherapy for Primary Pediatric Central Nervous System Malignancies: Current Treatment Paradigms and Future Directions. Abstract

  29. Clinical outcomes of radiation therapy for transgender and gender-expansive people with cancer. Front Oncol. 2023; 13:1135400. View Clinical outcomes of radiation therapy for transgender and gender-expansive people with cancer. Abstract

  30. Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30600. View Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. Abstract

  31. Children's Oncology Group's 2023 blueprint for research: Radiation oncology. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30593. View Children's Oncology Group's 2023 blueprint for research: Radiation oncology. Abstract

  32. Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1174-1180. View Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy. Abstract

  33. Serum miRNA-based signature indicates radiation exposure and dose in humans: A multicenter diagnostic biomarker study. Radiother Oncol. 2023 08; 185:109731. View Serum miRNA-based signature indicates radiation exposure and dose in humans: A multicenter diagnostic biomarker study. Abstract

  34. Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Neuro Oncol. 2023 06 02; 25(6):1100-1112. View Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Abstract

  35. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Neuro Oncol. 2023 05 04; 25(5):973-983. View Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Abstract

  36. Feasibility of the Audio-Visual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) System for Anesthesia Avoidance in Pediatric Patients: A Multicenter Trial. Int J Radiat Oncol Biol Phys. 2023 09 01; 117(1):96-104. View Feasibility of the Audio-Visual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) System for Anesthesia Avoidance in Pediatric Patients: A Multicenter Trial. Abstract

  37. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023 Feb; 36:100857. View Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Abstract

  38. Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. Int J Radiat Oncol Biol Phys. 2023 04 01; 115(5):1115-1128. View Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. Abstract

  39. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 2022 09 12; 40(9):957-972.e10. View A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Abstract

  40. Trends in location of death for individuals with primary brain tumors in the United States. Neuro Oncol. 2022 08 01; 24(8):1400-1401. View Trends in location of death for individuals with primary brain tumors in the United States. Abstract

  41. Clinical outcomes and considerations of gender-affirming care for transgender and gender-diverse pediatric and young adult patients with cancer. Pediatr Blood Cancer. 2023 01; 70(1):e29851. View Clinical outcomes and considerations of gender-affirming care for transgender and gender-diverse pediatric and young adult patients with cancer. Abstract

  42. Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac073. View Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. Abstract

  43. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510. View DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. Abstract

  44. "Per protocol" practice patterns for Children's Oncology Group trials within the radiation oncology community. Pediatr Blood Cancer. 2023 Aug; 70(8):e29673. View "Per protocol" practice patterns for Children's Oncology Group trials within the radiation oncology community. Abstract

  45. Predictors of long-term survival among patients with brain metastases. Neuro Oncol. 2022 03 12; 24(3):494-496. View Predictors of long-term survival among patients with brain metastases. Abstract

  46. Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. Phys Med Biol. 2022 03 11; 67(6). View Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. Abstract

  47. Breast and Cervical Cancer Screening Disparities in Transgender People. Am J Clin Oncol. 2022 03 01; 45(3):116-121. View Breast and Cervical Cancer Screening Disparities in Transgender People. Abstract

  48. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Radiat Res. 2022 Feb 01; 197(2):101-112. View Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Abstract

  49. A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):143-151. View A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. Abstract

  50. Gender, Productivity, and Philanthropic Fundraising in Academic Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1401-1406. View Gender, Productivity, and Philanthropic Fundraising in Academic Oncology. Abstract

  51. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021 11 02; 23(11):1872-1884. View Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Abstract

  52. Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis. Neurooncol Pract. 2022 Apr; 9(2):114-122. View Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis. Abstract

  53. Update on Radiation Therapy for Central Nervous System Tumors. Hematol Oncol Clin North Am. 2022 02; 36(1):77-93. View Update on Radiation Therapy for Central Nervous System Tumors. Abstract

  54. Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. Pediatr Blood Cancer. 2022 02; 69(2):e29396. View Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. Abstract

  55. Clinical outcomes for pediatric patients receiving radiotherapy for solid tumor central nervous system metastases. Pediatr Blood Cancer. 2021 12; 68(12):e29331. View Clinical outcomes for pediatric patients receiving radiotherapy for solid tumor central nervous system metastases. Abstract

  56. Harnessing Lactate Metabolism for Radiosensitization. Front Oncol. 2021; 11:672339. View Harnessing Lactate Metabolism for Radiosensitization. Abstract

  57. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. View Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Abstract

  58. Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Neurooncol Pract. 2021 Oct; 8(5):569-580. View Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Abstract

  59. Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021 04 12; 23(4):661-676. View Population-based estimates of survival among elderly patients with brain metastases. Abstract

  60. Long-term outcomes of pediatric and young adult patients receiving radiotherapy for nonmalignant vascular anomalies. Pediatr Blood Cancer. 2021 06; 68(6):e28955. View Long-term outcomes of pediatric and young adult patients receiving radiotherapy for nonmalignant vascular anomalies. Abstract

  61. Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. J Neurol Neurosurg Psychiatry. 2021 Mar 09. View Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. Abstract

  62. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304. View Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. Abstract

  63. Seizures Among Patients With Brain Metastases: A Population- and Institutional-Level Analysis. Neurology. 2021 Feb 22; 96(8):e1237-e1250. View Seizures Among Patients With Brain Metastases: A Population- and Institutional-Level Analysis. Abstract

  64. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 08; 68(8):e28930. View Outcomes after first relapse of childhood intracranial ependymoma. Abstract

  65. Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles. Mol Cancer Ther. 2021 04; 20(4):726-738. View Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles. Abstract

  66. Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer. JAMA Oncol. 2021 Jan 01; 7(1):e205671. View Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer. Abstract

  67. Hospice Utilization in Elderly Patients With Brain Metastases. J Natl Cancer Inst. 2020 12 14; 112(12):1251-1258. View Hospice Utilization in Elderly Patients With Brain Metastases. Abstract

  68. Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1396-1405. View Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. Abstract

  69. Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals. Eur Urol. 2021 05; 79(5):588-592. View Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals. Abstract

  70. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):726-735. View A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. Abstract

  71. Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Neuro Oncol. 2020 10 14; 22(10):1547-1548. View Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Abstract

  72. Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract. 2021 Feb; 8(1):68-74. View Reirradiation practices for children with diffuse intrinsic pontine glioma. Abstract

  73. What HIV/AIDS Taught Me About Pandemics: A Clinician's Perspective. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):346-347. View What HIV/AIDS Taught Me About Pandemics: A Clinician's Perspective. Abstract

  74. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. J Pediatr Hematol Oncol. 2020 10; 42(7):e647-e654. View Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. Abstract

  75. Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. Neuro Oncol. 2020 09 29; 22(9):1339-1347. View Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. Abstract

  76. Gliomas, germ cell tumors, and craniopharyngioma. Pediatr Blood Cancer. 2021 05; 68 Suppl 2:e28401. View Gliomas, germ cell tumors, and craniopharyngioma. Abstract

  77. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 12 15; 126(24):5274-5282. View Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Abstract

  78. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 09 01; 6(9):1465-1468. View Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. Abstract

  79. Artificial intelligence in radiation oncology. Nat Rev Clin Oncol. 2020 12; 17(12):771-781. View Artificial intelligence in radiation oncology. Abstract

  80. Practice patterns and recommendations for pediatric image-guided radiotherapy: A Children's Oncology Group report. Pediatr Blood Cancer. 2020 10; 67(10):e28629. View Practice patterns and recommendations for pediatric image-guided radiotherapy: A Children's Oncology Group report. Abstract

  81. Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. Med Dosim. 2021 Spring; 46(1):21-28. View Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. Abstract

  82. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 Aug 06. View Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. Abstract

  83. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. Abstract

  84. Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process. Cancer. 2020 09 01; 126(17):3896-3899. View Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process. Abstract

  85. Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. J Neurooncol. 2020 Jul; 148(3):509-517. View Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. Abstract

  86. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523. View Mechanisms and therapeutic implications of hypermutation in gliomas. Abstract

  87. Utility of claims data for identification of date of diagnosis of brain metastases. Neuro Oncol. 2020 04 15; 22(4):575-576. View Utility of claims data for identification of date of diagnosis of brain metastases. Abstract

  88. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clin Cancer Res. 2020 03 15; 26(6):1213-1219. View Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Abstract

  89. Cooperative Blockade of PKCa and JAK2 Drives Apoptosis in Glioblastoma. Cancer Res. 2020 02 15; 80(4):709-718. View Cooperative Blockade of PKCa and JAK2 Drives Apoptosis in Glioblastoma. Abstract

  90. Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. J Clin Oncol. 2019 12 10; 37(35):3335-3339. View Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. Abstract

  91. Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. Int J Radiat Oncol Biol Phys. 2019 12 01; 105(5):1034-1042. View Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. Abstract

  92. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. View Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. Abstract

  93. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731. View Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Abstract

  94. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract. 2020 Jan; 7(1):4-10. View Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Abstract

  95. A Central Role of Radiation Therapy in Central Nervous System Germinoma. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):970-971. View A Central Role of Radiation Therapy in Central Nervous System Germinoma. Abstract

  96. Clinical Impact of Tumor Mutational Burden in Neuroblastoma. J Natl Cancer Inst. 2019 07 01; 111(7):695-699. View Clinical Impact of Tumor Mutational Burden in Neuroblastoma. Abstract

  97. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. Breast Cancer Res Treat. 2019 Jul; 176(1):171-179. View Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. Abstract

  98. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. View Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Abstract

  99. Moody D. Wharam Jr, MD, FACR, FASTRO, July 22, 1941-August 10, 2018. Int J Radiat Oncol Biol Phys. 2019 Apr 01; 103(5):1026-1030. View Moody D. Wharam Jr, MD, FACR, FASTRO, July 22, 1941-August 10, 2018. Abstract

  100. Towards a standard of care in oncology for transgender patients. Lancet Oncol. 2019 03; 20(3):331-333. View Towards a standard of care in oncology for transgender patients. Abstract

  101. Local control after brain-directed radiation in patients with cystic versus solid brain metastases. J Neurooncol. 2019 Apr; 142(2):355-363. View Local control after brain-directed radiation in patients with cystic versus solid brain metastases. Abstract

  102. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019 02; 31(1):21-27. View Management of pediatric low-grade glioma. Abstract

  103. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nat Commun. 2019 01 25; 10(1):442. View The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Abstract

  104. Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 2019 04 15; 125(8):1357-1364. View Risk stratification by somatic mutation burden in Ewing sarcoma. Abstract

  105. Larry Emanuel Kun, March 10, 1946-May 27, 2018. Int J Radiat Oncol Biol Phys. 2019 Jan 01; 103(1):8-14. View Larry Emanuel Kun, March 10, 1946-May 27, 2018. Abstract

  106. Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. World Neurosurg. 2019 Feb; 122:e1557-e1561. View Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. Abstract

  107. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018 Dec; 140(3):629-638. View Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. Abstract

  108. Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021. View Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Abstract

  109. National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):152-168. View National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. Abstract

  110. Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches-Meeting Viewpoint. Cancer Res. 2018 05 01; 78(9):2166-2170. View Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches-Meeting Viewpoint. Abstract

  111. Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors. J Child Neurol. 2018 04; 33(5):359-366. View Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors. Abstract

  112. The Future of Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):329-340. View The Future of Radiobiology. Abstract

  113. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 07; 65(7):e27023. View Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Abstract

  114. The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):860-874. View The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer. Abstract

  115. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 03; 126(3):511-518. View Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Abstract

  116. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521. View Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Abstract

  117. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Mol Cancer Ther. 2018 02; 17(2):347-354. View Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Abstract

  118. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget. 2017 Oct 17; 8(49):84697-84713. View Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Abstract

  119. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Transl Res. 2017 10; 188:27.e1-27.e14. View Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Abstract

  120. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017 Aug 01; 3(8):1069-1077. View Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. Abstract

  121. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 01; 123(23):4631-4639. View Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Abstract

  122. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. Abstract

  123. Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Radiat Res. 2017 09; 188(3):303-313. View Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Abstract

  124. A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies. J Clin Oncol. 2017 08 01; 35(22):2471-2472. View A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies. Abstract

  125. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017 06 01; 19(6):750-761. View Pediatric low-grade gliomas: implications of the biologic era. Abstract

  126. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):468-475. View Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. Abstract

  127. Reply to J. Stenman et al. J Clin Oncol. 2017 06 10; 35(17):1966-1967. View Reply to J. Stenman et al. Abstract

  128. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol. 2017 Sep; 134(3):541-549. View Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. Abstract

  129. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 2017 03 13; 31(3):424-435. View A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Abstract

  130. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251. View Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Abstract

  131. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017 02 01; 19(2):153-161. View Pediatric high-grade glioma: biologically and clinically in need of new thinking. Abstract

  132. Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 10; 35(2):208-216. View Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. Abstract

  133. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Abstract

  134. Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. J Neurooncol. 2017 01; 131(2):359-368. View Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. Abstract

  135. Acute pain management in radiation oncology: Quality of care and the impact of an integrated palliative oncology service. J Clin Oncol. 2016 Oct 09; 34(26_suppl):195. View Acute pain management in radiation oncology: Quality of care and the impact of an integrated palliative oncology service. Abstract

  136. Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro Oncol. 2016 11; 18(11):1548-1558. View Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Abstract

  137. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol. 2016 11; 18(11):1519-1528. View Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Abstract

  138. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017 01; 19(1):78-88. View Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Abstract

  139. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Clin Cancer Res. 2016 11 01; 22(21):5312-5321. View BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Abstract

  140. Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Future Oncol. 2016 Jun; 12(12):1493-506. View Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Abstract

  141. Therapeutic radiation and the potential risk of second malignancies. Cancer. 2016 Jun 15; 122(12):1809-21. View Therapeutic radiation and the potential risk of second malignancies. Abstract

  142. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82. View MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Abstract

  143. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):395. View Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Abstract

  144. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200. View Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. Abstract

  145. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):385-93. View Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Abstract

  146. WEE1 Kinase As a Target for Cancer Therapy. J Clin Oncol. 2015 Oct 20; 33(30):3485-7. View WEE1 Kinase As a Target for Cancer Therapy. Abstract

  147. Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):217-9. View Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. Abstract

  148. Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. Strahlenther Onkol. 2015 Jul; 191(7):604-12. View Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. Abstract

  149. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. View Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Abstract

  150. Toward an improved understanding of the ionizing radiation induced DNA damage/response networks in human malignancies. Front Oncol. 2014; 4:335. View Toward an improved understanding of the ionizing radiation induced DNA damage/response networks in human malignancies. Abstract

  151. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):259-64. View Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Abstract

  152. Preface. High-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):233-4. View Preface. High-grade gliomas. Abstract

  153. Pure germinomas of the central nervous system: treatment strategies and outcomes. J Neurooncol. 2014 Dec; 120(3):643-9. View Pure germinomas of the central nervous system: treatment strategies and outcomes. Abstract

  154. Non-Muscle Myosin IIa Heavy Chain Links Squamous-Cell Carcinoma of the Head and Neck to the DNA Damage Response. Front Oncol. 2014; 4:228. View Non-Muscle Myosin IIa Heavy Chain Links Squamous-Cell Carcinoma of the Head and Neck to the DNA Damage Response. Abstract

  155. Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. J Child Neurol. 2015 Jun; 30(7):842-849. View Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. Abstract

  156. SU-E-T-371: Validation of Organ Doses Delivered During Craniospinal Irradiation with Helical Tomotherapy. Med Phys. 2014 Jun; 41(6):310. View SU-E-T-371: Validation of Organ Doses Delivered During Craniospinal Irradiation with Helical Tomotherapy. Abstract

  157. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):839-45. View Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Abstract

  158. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51. View Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: single-institution prospective study at University of California, San Francisco. Abstract

  159. Oncology scan--Molecular genotyping of medulloblastoma: a new treatment era. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):229-31. View Oncology scan--Molecular genotyping of medulloblastoma: a new treatment era. Abstract

  160. In reply to Bull et al. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):434. View In reply to Bull et al. Abstract

  161. Hyperfractionation: fractious or not? Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):269-71. View Hyperfractionation: fractious or not? Abstract

  162. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol. 2014 Jan; 16(2):173-8. View Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Abstract

  163. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol. 2014 Mar; 16(3):352-60. View Targeting Wee1 for the treatment of pediatric high-grade gliomas. Abstract

  164. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. View Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Abstract

  165. The subventricular zone neural progenitor cell hypothesis in glioblastoma: epiphany, Trojan Horse, or Cheshire fact? Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):606-8. View The subventricular zone neural progenitor cell hypothesis in glioblastoma: epiphany, Trojan Horse, or Cheshire fact? Abstract

  166. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst. 2013 Aug; 29(8):1313-9. View Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Abstract

  167. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol. 2013; 3:110. View The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Abstract

  168. Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):643-8. View Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy. Abstract

  169. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013 Sep; 23(5):565-73. View PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Abstract

  170. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res. 2013 Mar; 33(3):755-62. View Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Abstract

  171. Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol. 2013 Feb; 9(2):219-33. View Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Abstract

  172. Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs. 2013 Oct; 31(5):1136-41. View Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Abstract

  173. Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer. 2013 Jun; 60(6):1022-6. View Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Abstract

  174. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012 Dec; 14(6):735-42. View Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Abstract

  175. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 2012; 6:207-19. View Hepatocellular carcinoma: natural history, current management, and emerging tools. Abstract

  176. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol. 2012 Sep; 14(9):1146-52. View PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Abstract

  177. High-grade gliomas in children. Neurosurg Clin N Am. 2012 Jul; 23(3):515-23. View High-grade gliomas in children. Abstract

  178. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol. 2012 May; 108(1):133-9. View The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. Abstract

  179. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):315-25. View Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Abstract

  180. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan; 106(2):367-75. View Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. Abstract

  181. PARP-1 inhibitor MK-4827 in combination with radiation as a treatment strategy for metastatic neuroblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):9559. View PARP-1 inhibitor MK-4827 in combination with radiation as a treatment strategy for metastatic neuroblastoma. Abstract

  182. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9. View Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Abstract

  183. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15; 17(8):2339-49. View Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Abstract

  184. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011 Sep 15; 117(18):4286-93. View Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Abstract

  185. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol. 2011 Mar; 13(3):280-9. View DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Abstract

  186. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011 Mar; 13(3):298-306. View Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Abstract

  187. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr; 13(4):384-92. View Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Abstract

  188. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011 Apr; 13(4):417-27. View MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Abstract

  189. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011 Feb; 52(2):188-95. View Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. Abstract

  190. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 2010 Nov 09; 3(147):ra81. View Akt and autophagy cooperate to promote survival of drug-resistant glioma. Abstract

  191. DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Childs Nerv Syst. 2011 Jan; 27(1):11-8. View DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Abstract

  192. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Rev Mol Diagn. 2010 Oct; 10(7):883-95. View Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Abstract

  193. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010 Sep; 37(9):4861-7. View Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Abstract

  194. Radiation dose estimation using preclinical imaging with I124-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010 Sep; 37(9):4861-4867. View Radiation dose estimation using preclinical imaging with I124-metaiodobenzylguanidine (MIBG) PET. Abstract

  195. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol. 2010 Oct; 100(1):121-7. View Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. Abstract

  196. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010 Feb 15; 70(4):1296-305. View Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Abstract

  197. Radiation-induced gliomas. Expert Rev Neurother. 2009 Oct; 9(10):1511-7. View Radiation-induced gliomas. Abstract

  198. Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. Pediatr Radiol. 2009 Nov; 39(11):1194-202. View Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. Abstract

  199. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010 Mar; 97(1):33-40. View Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. Abstract

  200. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):177-82. View Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Abstract

  201. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal. 2009 Jan 27; 2(55):ra4. View EGFR signals to mTOR through PKC and independently of Akt in glioma. Abstract

  202. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 01; 27(7):1007-13. View Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. Abstract

  203. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jan; 52(1):44-50. View Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Abstract

  204. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res. 2008 Dec 15; 68(24):10034-9. View p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Abstract

  205. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009 Feb 01; 27(4):579-84. View Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Abstract

  206. Signal transduction molecules in gliomas of all grades. J Neurooncol. 2009 Jan; 91(1):19-26. View Signal transduction molecules in gliomas of all grades. Abstract

  207. 15-year results for upfront TPDCV chemotherapy phase II trial for pediatric low-grade hypothalamic/chiasmatic gliomas. J Clin Oncol. 2008 May 20; 26(15_suppl):10041. View 15-year results for upfront TPDCV chemotherapy phase II trial for pediatric low-grade hypothalamic/chiasmatic gliomas. Abstract

  208. Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1319-23. View Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Abstract

  209. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008 Jun; 10(3):341-7. View Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Abstract

  210. Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008 Apr; 7(4):841-50. View Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Abstract

  211. PTEN in brain tumors. Expert Rev Neurother. 2008 Apr; 8(4):599-610. View PTEN in brain tumors. Abstract

  212. Glioma invasiveness responds variably to irradiation in a co-culture model. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):880-6. View Glioma invasiveness responds variably to irradiation in a co-culture model. Abstract

  213. Nutrient-sensitive, antagonistically pleiotropic genes and their contribution to malignant behavior. Med Hypotheses. 2008; 70(2):444-53. View Nutrient-sensitive, antagonistically pleiotropic genes and their contribution to malignant behavior. Abstract

  214. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):858-64. View Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Abstract

  215. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007 Jul; 9(3):271-9. View Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Abstract

  216. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol. 2007 Apr; 9(2):82-8. View In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Abstract

  217. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Lett. 2007 Aug 18; 253(2):205-14. View AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Abstract

  218. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol. 2007 Feb 14; 13(6):895-900. View Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. Abstract

  219. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest New Drugs. 2006 Sep; 24(5):383-92. View The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Abstract

  220. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res. 2006 May; 4(5):319-30. View Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Abstract

  221. Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res. 2006 Apr 15; 66(8):4223-32. View Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Abstract

  222. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol. 2006 Apr; 8(2):166-74. View The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Abstract

  223. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma. 2006; 2006(1):91671. View Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Abstract

  224. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther. 2005 Dec; 4(12):1952-61. View Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Abstract

  225. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys. 2005 Nov 15; 63(4):1221-7. View Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Abstract

  226. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. View Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. Abstract

  227. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005 Oct; 4(10):1369-72. View Biomarkers to predict response to epidermal growth factor receptor inhibitors. Abstract

  228. High failure rate in spinal ependymomas with long-term follow-up. Neuro Oncol. 2005 Jul; 7(3):254-9. View High failure rate in spinal ependymomas with long-term follow-up. Abstract

  229. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005 Jun 15; 97(12):880-7. View Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. Abstract

  230. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):207-12. View Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. Abstract

  231. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):20-31. View Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. Abstract

  232. Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1183-8. View Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism. Abstract

  233. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol. 2005 Feb; 71(3):215-22. View PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. Abstract

  234. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell. 2004 Nov; 15(11):4841-53. View Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Abstract

  235. High failure rate in spinal ependymomas with long-term follow-up. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1528. View High failure rate in spinal ependymomas with long-term follow-up. Abstract

  236. Berberine sensitizes human glioma cells, but not normal glial cells, to ionizing radiation in vitro. J Exp Ther Oncol. 2004 Jul; 4(2):137-43. View Berberine sensitizes human glioma cells, but not normal glial cells, to ionizing radiation in vitro. Abstract

  237. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol. 2003 Nov; 23(22):8306-15. View The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Abstract

  238. Radiation therapy for intracranial germ cell tumors. Int J Radiat Oncol Biol Phys. 2003 Jun 01; 56(2):511-8. View Radiation therapy for intracranial germ cell tumors. Abstract

  239. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):28-39. View Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Abstract

  240. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 2003 Jan 01; 63(1):236-41. View PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Abstract

  241. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res. 2002 May; 8(5):1100-6. View Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Abstract

  242. Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene. 2001 May 17; 20(22):2826-35. View Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Abstract

  243. Functional and clinical outcomes of limb-sparing therapy for pediatric extremity sarcomas. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):763-9. View Functional and clinical outcomes of limb-sparing therapy for pediatric extremity sarcomas. Abstract

  244. p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res. 2001 Mar 01; 61(5):2105-11. View p27Kip1 is required for PTEN-induced G1 growth arrest. Abstract

  245. Intraoperative radiation therapy for high-risk pediatric neuroblastoma. Int J Radiat Oncol Biol Phys. 2000 Jul 01; 47(4):985-92. View Intraoperative radiation therapy for high-risk pediatric neuroblastoma. Abstract

  246. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000 Feb 15; 14(4):391-6. View Loss of PTEN facilitates HIF-1-mediated gene expression. Abstract

  247. Overexpression of E2F1 in glioma-derived cell lines induces a p53-independent apoptosis that is further enhanced by ionizing radiation. Neuro Oncol. 2000 01; 2(1):16-21. View Overexpression of E2F1 in glioma-derived cell lines induces a p53-independent apoptosis that is further enhanced by ionizing radiation. Abstract

  248. Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells. Cancer Res. 1999 Mar 15; 59(6):1362-5. View Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells. Abstract

  249. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):399-403. View p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Abstract

  250. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998 Oct 22; 8(21):1195-8. View Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Abstract

  251. Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy. Cancer Res. 1998 Sep 01; 58(17):3819-25. View Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy. Abstract

  252. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys. 1996 Aug 01; 36(1):95-103. View p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Abstract

  253. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat Res. 1996 Mar; 145(3):289-98. View Cytogenetic damage and the radiation-induced G1-phase checkpoint. Abstract

  254. P53-independent apoptosis: a mechanism of radiation-induced cell death of glioblastoma cells. Cancer J Sci Am. 1996 Mar-Apr; 2(2):114-21. View P53-independent apoptosis: a mechanism of radiation-induced cell death of glioblastoma cells. Abstract

  255. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res. 1996 Feb 01; 56(3):500-6. View Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Abstract

  256. Inactivation of p53 is associated with decreased levels of radiation-induced apoptosis in medulloblastoma cell lines. Cell Death Differ. 1995 Oct; 2(4):267-75. View Inactivation of p53 is associated with decreased levels of radiation-induced apoptosis in medulloblastoma cell lines. Abstract

  257. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J. 1995 Feb 01; 14(3):461-72. View Inhibition of apoptosis by the retinoblastoma gene product. Abstract

BESbswy